On June 10, Gelonghui reported that InnoCare Pharma-B (09606.HK) announced that the Board of Directors was aware of the fluctuations in the Fill Price and Volume of the company's shares on the Stock Exchange on June 9 and June 10, 2025. The Board also learned that the company published a news article on its website on June 5, 2025, regarding preliminary data on ADC candidate drugs announced in a verbal report at the 2025 American Society of Clinical Oncology (ASCO) annual meeting.
After making all reasonable inquiries regarding the company in this context, the Board of Directors confirmed that (i) the information contained in the news article does not constitute inside information under the provisions of Listing Rule 13.09(2) or Part XIVA of the Securities and Futures Ordinance (Cap. 571) of Hong Kong; (ii) it is not aware of any reasons for the fluctuations in the Fill Price and Volume of the shares, or of any information that must be disclosed to avoid a false market in the company's securities, or any inside information that must be disclosed; and (iii) the company's operations are functioning normally.
